InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| MSU Crystals | Ptychographic lens-less birefringence microscopy using a mask-modulated polar... | 2023 | Sci Rep. | Kim J. et al. | DOI: 10.1038/s41598-023-46496-z |
| Nigericin | Panton-Valentine leukocidin-induced neutrophil extracellular traps lack antim... | 2023 | J Leukoc Biol. | Jhelum H. et al. | DOI: 10.1093/jleuko/qiad137 |
| RU.521 | An IKBKE variant conferring functional cGAS/STING pathway deficiency and susc... | 2023 | JCI Insight | Reyahi A. et al. | DOI: 10.1172/jci.insight.173066 |
| Poly(I:C) LMW | An IKBKE variant conferring functional cGAS/STING pathway deficiency and susc... | 2023 | JCI Insight | Reyahi A. et al. | DOI: 10.1172/jci.insight.173066 |
| 2'3'-cGAMP | An IKBKE variant conferring functional cGAS/STING pathway deficiency and susc... | 2023 | JCI Insight | Reyahi A. et al. | DOI: 10.1172/jci.insight.173066 |
| Amlexanox | An IKBKE variant conferring functional cGAS/STING pathway deficiency and susc... | 2023 | JCI Insight | Reyahi A. et al. | DOI: 10.1172/jci.insight.173066 |
| BX795 | An IKBKE variant conferring functional cGAS/STING pathway deficiency and susc... | 2023 | JCI Insight | Reyahi A. et al. | DOI: 10.1172/jci.insight.173066 |
| Jurkat-Dual™ Cells | Activation of the Interleukin-18 Signaling Pathway via Direct Receptor Dimeri... | 2023 | J Interferon Cytokine Res. | Mortazavi Y. et al. | DOI: 10.1089/jir.2023.0129 |
| Puromycin | Development of IFNβ-1a versions with reduced immunogenicity and full in vitro... | 2023 | Clin Immunol. | Ricotti S. et al. | DOI: 10.1016/j.clim.2023.109831 |
| QUANTI-Blue™ | Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of... | 2023 | Cells | Harless W.W. et al. | DOI: 10.3390/cells12091332 |
| RAW-Blue™ Cells | Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of... | 2023 | Cells | Harless W.W. et al. | DOI: 10.3390/cells12091332 |
| Puromycin | Distinct molecular mechanisms contribute to the reduction of melanoma growth ... | 2023 | FASEB J. | Niederberger E. et al. | DOI: 10.1096/fj.202301489R |
| EndoFit™ OVA protein | Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equi... | 2023 | Int J Pharm. | Hellfritzsch M. et al. | DOI: 10.1016/j.ijpharm.2023.123581 |
| Alhydrogel® adjuvant 2% | Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equi... | 2023 | Int J Pharm. | Hellfritzsch M. et al. | DOI: 10.1016/j.ijpharm.2023.123581 |
| ODN 1826 VacciGrade™ | Development of a Tag/Catcher-mediated capsid virus-like particle vaccine pres... | 2023 | Infect Immun. | Martinez F.G. et al. | DOI: 10.1128/iai.00245-23 |
| AddaVax™ | Development of a Tag/Catcher-mediated capsid virus-like particle vaccine pres... | 2023 | Infect Immun. | Martinez F.G. et al. | DOI: 10.1128/iai.00245-23 |
| Zeocin® | Effect of nitro-conjugated linoleic acid on the inflammatory response of muri... | 2023 | Inflammopharmacology. | Lee J.E. et al. | DOI: 10.1007/s10787-023-01340-8 |
| 293-Dual™ hSTING-R232 Cells | ARF1 prevents aberrant type I interferon induction by regulating STING activa... | 2023 | Nat Commun. | Hirschenberger M. et al. | DOI: 10.1038/s41467-023-42150-4 |
| THP1-Dual™ KO-cGAS Cells | ARF1 prevents aberrant type I interferon induction by regulating STING activa... | 2023 | Nat Commun. | Hirschenberger M. et al. | DOI: 10.1038/s41467-023-42150-4 |
| THP1-Dual™ Cells | ARF1 prevents aberrant type I interferon induction by regulating STING activa... | 2023 | Nat Commun. | Hirschenberger M. et al. | DOI: 10.1038/s41467-023-42150-4 |